BACKGROUND A frequent complication of anticancer treatment, oral and gastrointestinal
(GI) mucositis, threatens the effectiveness of therapy because it leads to dose reductions …

Solvent-based delivery vehicles for chemotherapy agents have been instrumental in
providing a means for hydrophobic agents to be administered intravenously. These solvents …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional …

Purpose This randomized, multicenter trial compared first-line trastuzumab plus docetaxel
versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) …

Purpose To update the 2000 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSF). Update Methodology The Update …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
trials that have demonstrated a survival benefit with a modern chemotherapeutic agent or …

Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of
what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact …

Background We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with
fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for …

Breast cancer is the most common cancer in women in almost all countries, including
developing countries. In 2008, 1 380 000 new cases and 458 000 breast cancer deaths …